191 related articles for article (PubMed ID: 27770789)
1. A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile.
Zhang BZ; Cai J; Yu B; Hua Y; Lau CC; Kao RY; Sze KH; Yuen KY; Huang JD
BMC Infect Dis; 2016 Oct; 16(1):596. PubMed ID: 27770789
[TBL] [Abstract][Full Text] [Related]
2. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.
Tian JH; Fuhrmann SR; Kluepfel-Stahl S; Carman RJ; Ellingsworth L; Flyer DC
Vaccine; 2012 Jun; 30(28):4249-58. PubMed ID: 22537987
[TBL] [Abstract][Full Text] [Related]
3. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile.
Donald RGK; Flint M; Kalyan N; Johnson E; Witko SE; Kotash C; Zhao P; Megati S; Yurgelonis I; Lee PK; Matsuka YV; Severina E; Deatly A; Sidhu M; Jansen KU; Minton NP; Anderson AS
Microbiology (Reading); 2013 Jul; 159(Pt 7):1254-1266. PubMed ID: 23629868
[TBL] [Abstract][Full Text] [Related]
4. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
Wang H; Sun X; Zhang Y; Li S; Chen K; Shi L; Nie W; Kumar R; Tzipori S; Wang J; Savidge T; Feng H
Infect Immun; 2012 Aug; 80(8):2678-88. PubMed ID: 22615245
[TBL] [Abstract][Full Text] [Related]
5. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome.
Ng J; Hirota SA; Gross O; Li Y; Ulke-Lemee A; Potentier MS; Schenck LP; Vilaysane A; Seamone ME; Feng H; Armstrong GD; Tschopp J; Macdonald JA; Muruve DA; Beck PL
Gastroenterology; 2010 Aug; 139(2):542-52, 552.e1-3. PubMed ID: 20398664
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease.
Ghose C; Verhagen JM; Chen X; Yu J; Huang Y; Chenesseau O; Kelly CP; Ho DD
Infect Immun; 2013 Jun; 81(6):2190-6. PubMed ID: 23545305
[TBL] [Abstract][Full Text] [Related]
7. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.
Yang XQ; Zhao YG; Chen XQ; Jiang B; Sun DY
BMC Gastroenterol; 2013 Jul; 13():117. PubMed ID: 23865596
[TBL] [Abstract][Full Text] [Related]
8. Emerging toxin A-B+ variant strain of Clostridium difficile responsible for pseudomembranous colitis at a tertiary care hospital in Korea.
Shin BM; Kuak EY; Yoo SJ; Shin WC; Yoo HM
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):333-7. PubMed ID: 18082994
[TBL] [Abstract][Full Text] [Related]
9. Comparison of VIDAS CDAB and CDA immunoassay for the detection of Clostridium difficile in a tcdA- tcdB+ C. difficile prevalent area.
Shin BM; Lee EJ; Kuak EY; Yoo SJ
Anaerobe; 2009 Dec; 15(6):266-9. PubMed ID: 19772927
[TBL] [Abstract][Full Text] [Related]
10. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection.
Persson S; Torpdahl M; Olsen KE
Clin Microbiol Infect; 2008 Nov; 14(11):1057-64. PubMed ID: 19040478
[TBL] [Abstract][Full Text] [Related]
11. [Investigation of toxin genes of Clostridium difficile strains isolated from hospitalized patients with diarrhoea at Marmara University Hospital].
Deniz U; Ulger N; Aksu B; Karavuş M; Söyletir G
Mikrobiyol Bul; 2011 Jan; 45(1):1-10. PubMed ID: 21341153
[TBL] [Abstract][Full Text] [Related]
12. Multicentre study of the prevalence of toxigenic Clostridium difficile in Korea: results of a retrospective study 2000-2005.
Shin BM; Kuak EY; Yoo HM; Kim EC; Lee K; Kang JO; Whang DH; Shin JH
J Med Microbiol; 2008 Jun; 57(Pt 6):697-701. PubMed ID: 18480325
[TBL] [Abstract][Full Text] [Related]
13. Novel Chimeric Protein Vaccines Against
Wang S; Wang Y; Cai Y; Kelly CP; Sun X
Front Immunol; 2018; 9():2440. PubMed ID: 30405630
[No Abstract] [Full Text] [Related]
14. Molecular cloning, overexpression in Escherichia coli, and purification of 6x his-tagged C-terminal domain of Clostridium difficile toxins A and B.
Letourneur O; Ottone S; Delauzun V; Bastide MC; Foussadier A
Protein Expr Purif; 2003 Oct; 31(2):276-85. PubMed ID: 14550648
[TBL] [Abstract][Full Text] [Related]
15. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.
Hirota SA; Iablokov V; Tulk SE; Schenck LP; Becker H; Nguyen J; Al Bashir S; Dingle TC; Laing A; Liu J; Li Y; Bolstad J; Mulvey GL; Armstrong GD; MacNaughton WK; Muruve DA; MacDonald JA; Beck PL
Infect Immun; 2012 Dec; 80(12):4474-84. PubMed ID: 23045481
[TBL] [Abstract][Full Text] [Related]
16. Detection and transcription of toxin DNA in a nontoxigenic strain of Clostridium difficile.
Mathis JN; Pilkinton L; McMillin DE
Curr Microbiol; 1999 Jun; 38(6):324-8. PubMed ID: 10341072
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the pathogenicity locus in Clostridium difficile strains.
Cohen SH; Tang YJ; Silva J
J Infect Dis; 2000 Feb; 181(2):659-63. PubMed ID: 10669352
[TBL] [Abstract][Full Text] [Related]
18. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile.
Lemee L; Dhalluin A; Testelin S; Mattrat MA; Maillard K; Lemeland JF; Pons JL
J Clin Microbiol; 2004 Dec; 42(12):5710-4. PubMed ID: 15583303
[TBL] [Abstract][Full Text] [Related]
19. Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains.
Secore S; Wang S; Doughtry J; Xie J; Miezeiewski M; Rustandi RR; Horton M; Xoconostle R; Wang B; Lancaster C; Kristopeit A; Wang SC; Christanti S; Vitelli S; Gentile MP; Goerke A; Skinner J; Strable E; Thiriot DS; Bodmer JL; Heinrichs JH
PLoS One; 2017; 12(1):e0170640. PubMed ID: 28125650
[TBL] [Abstract][Full Text] [Related]
20. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
